Search

Legend Biotech Corp ADR

Slēgts

SektorsVeselības aprūpe

20.85 -4.45

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

21.64

Max

21.99

Galvenie mērījumi

By Trading Economics

Ienākumi

88M

33M

Pārdošana

82M

388M

EPS

0.09

Peļņas marža

8.568

Darbinieki

3,200

EBITDA

92M

60M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+120.3% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 11. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

4.9M

4B

Iepriekšējā atvēršanas cena

25.3

Iepriekšējā slēgšanas cena

20.85

Ziņu noskaņojums

By Acuity

100%

0%

328 / 340 Rangs Healthcare

Legend Biotech Corp ADR Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 21. aug. 23:01 UTC

Legend Biotech Corp shares are higher in after-market trading, maintaining a position near the upper end of their one-month trading range.

2026. g. 20. aug. 23:46 UTC

Legend Biotech Corp. shares are trading higher in after-market hours, diverging from broader market pressures amid rising crude oil prices and geopolitical tensions.

2026. g. 19. aug. 23:01 UTC

Legend Biotech Corp shares are higher in after-market trading, showing notable strength and exceeding the 20-day moving average. No specific news was identified.

2026. g. 18. aug. 20:03 UTC

Social Media

Legend Biotech Corp shares are higher today, buoyed by strong investor sentiment and analyst confidence in significant upside potential for the stock.

2026. g. 14. aug. 19:36 UTC

Shares of Legend Biotech Corp are trading higher, though fluctuations have been routine during the session. The stock remains below its 20-day moving average.

2026. g. 13. aug. 23:21 UTC

Legend Biotech Corp shares are higher in after-market hours, gaining traction following notable trading activity after Thursday's close. No specific news was identified.

2026. g. 12. aug. 23:16 UTC

Legend Biotech Corp. shares are higher in after-market hours, reflecting positive market conditions amid a Consumer Price Index report that met forecasts.

2026. g. 11. aug. 23:46 UTC

Shares of Legend Biotech Corp are higher in after-market hours, maintaining a position above the 20-day moving average amid stable trading conditions.

2026. g. 10. aug. 23:06 UTC

Shares of Legend Biotech are higher in after-market trading, settling above Monday's close despite mixed market sentiment and geopolitical tensions.

2026. g. 7. aug. 23:46 UTC

Shares of Legend Biotech Corp traded higher in after-market hours, amid a broader market context of a declining unemployment rate.

2026. g. 6. aug. 20:06 UTC

Legend Biotech Corp shares are higher today, reflecting a shift from recent trends. No specific company news was identified to explain this movement.

2026. g. 4. aug. 19:36 UTC

Legend Biotech Corp shares are higher today, recovering from an earlier low. Positive momentum persists despite a decline in U.S. core factory orders.

2026. g. 3. aug. 22:01 UTC

Shares of Legend Biotech Corp are higher in after-market trading, reflecting gains since Monday's close amid broader market advances in tech and oil-sensitive sectors.

2026. g. 31. jūl. 23:56 UTC

Shares of Legend Biotech Corp. are higher in after-market trading, despite a slight decline earlier in the session and broader market weakness.

2026. g. 30. jūl. 22:41 UTC

Shares of Legend Biotech Corp are trading lower in after-market hours, continuing a trend of unusual weakness since Thursday's close.

2026. g. 29. jūl. 19:27 UTC

Social Media

Legend Biotech Corp shares are lower, extending a four-session decline. Raymond James projects a 12-month price target range of $58 to $86.

2026. g. 28. jūl. 22:56 UTC

Shares of Legend Biotech Corp are trading higher in after-market hours, despite no specific news identified. The broader market showed gains earlier in the day.

2026. g. 27. jūl. 23:16 UTC

Legend Biotech Corp shares are higher in after-market hours, having briefly reached a session high. The price remains below its 20-day moving average.

2026. g. 24. jūl. 19:16 UTC

News

UBS downgraded Legend Biotech Corp to Neutral and cut its price target to $28, contributing to a decline in shares during Friday's session.

2026. g. 22. jūl. 18:31 UTC

Legend Biotech Corp shares are lower today amid broader market weakness and rising geopolitical tensions, despite an earlier peak during the session.

2026. g. 21. jūl. 16:46 UTC

Legend Biotech Corp. shares are higher today, reaching a session peak amid rising crude oil prices, despite trading below its 20-day moving average.

2026. g. 20. jūl. 19:01 UTC

Legend Biotech Corp is trading higher during Monday's session, rebounding from an earlier low and showing strength after a week of declines.

Salīdzinājums

Cenas izmaiņa

Legend Biotech Corp ADR Prognoze

Cenas mērķis

By TipRanks

120.3% augšup

Prognoze 12 mēnešiem

Vidējais 48.07 USD  120.3%

Augstākais 78 USD

Zemākais 24 USD

Pamatojoties uz 10 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Legend Biotech Corp ADR — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

10 ratings

6

Pirkt

4

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Legend Biotech Corp ADR

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.
help-icon Live chat